Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study
Source : https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00294-0/fulltext
Trigeminal neuralgia is a severe facial pain disorder that is difficult to treat. Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, has proven efficacy in migraine. Erenumab...
Interpretation: Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and CGRP probably does not have an important role in paroxysmal pain. Well tolerated, effective treatments in trigeminal neuralgia are still needed.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrGood to have information from around the world.
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01492-y
Background and aims Chronic migraine is a common neurovascular brain disorder with substantial economic costs. We performed a systematic review to identify economic evaluations of pharmacological treatments for adults with...
Conclusions: Evidence to support the cost-effectiveness of pharmacological treatments of chronic migraine in the adult population using Botox and Erenumab were identified. Our findings suggest that both Botox and Erenumab, are cost-effective compared to placebo; although Erenumab had more incremental economic benefits compared to Botox.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrVery interesting!
Serum CGRP in migraine patients using erenumab as preventive treatment - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01483-z
Aim Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response....
Conclusion: Lower serum CGRP-LI 2–4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrI think checking cGRP levels can be difficult and not clear if they will drive treatment.
-
Migraine Connect3yrWhat are your thoughts on checking CGRP-LI levels?
Show More Comments
TRIGEMINAL NEURALGIA FACIAL PAIN SYMPTOMS AND TREATMENTS - Virtual Headache Specialist
Source : https://virtualheadachespecialist.com/trigeminal-neuralgia-facial-pain-symptoms-and-treatments/
You are eating your lunch, biting into that delicious apple, when suddenly you have a severe electrical zapping shock across part of your face. You jerk your head back because...
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis can be very hard to treat.
NECK PAIN AND HEADACHE. THE TRIGEMINOCERVICAL NUCLEUS CONNECTION BETWEEN MIGRAINE, HEADACHE AND NECK PAIN. - Virtual Headache Specialist
Source : https://virtualheadachespecialist.com/neck-pain-and-headache-migraine-headache-and-neck-pain/
Can headache cause neck pain? Can neck pain cause headache? Do you have neck pain with a headache? What are neck pain headache causes? These are likely familiar questions if...